During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

More participants in the higher-dose group than placebo achieved an HbA1c under 7% (55.9% vs 15.2%) or under 6.5% (29.4% vs 6 ...

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin Newsom's initial timeline.

Say Manufacturers Ready To Bridge Impact Of GSK, Others Exit From Nigeria Nigerian Pharmaceutical companies are beginning to ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Medicare Part D spending for 10 selected diabetes drugs in the USA totaled $35.8 billion in 2023, an increase of 364% from ...

Type 1 Diabetes Market Rising Prevalence and Technological Advancements Drive Market Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...

Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney disease — ischemic ...